Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Editorial Volume 4 Issue 6

Treatment Options for Novel Corona Virus-Current guidelines in Clinical Settings of Pakistan

Nayab Mustansar* and Rizwan Rafi

Consultant Nuclear Physician, Department of Nuclear Medicine, Islamabad, Pakistan

*Corresponding Author: Nayab Mustansar, Consultant Nuclear Physician, Department of Nuclear Medicine, Islamabad, Pakistan.

Received: April 30, 2020; Published: May 02, 2019



  As of February 2020, new cases of COVID19 have been reported in Pakistan, Sindh province initially and then spread to the rest of provinces due to the Foreigners coming back to Pakistan [1]. At present unfortunately no vaccine has been developed moreover we don’t have any specific anti-viral for this novel corona virus [2-4]. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus [5-8]. Although till now the patients are being treated on symptomatic basis. Moreover, immune boosting drugs and diet has also been added and have shown positive results too.

Keywords:Treatment; Analgesics; Antibiotics; Antivirals; Immune Boosters; Coronavirus; Pneumonia



  1. National Health Commission of the People's Republic of China. “Pneumonia epidemic situation of new coronavirus infection” (2020).
  2. Natsuko Imai. “Report 2: Estimating the potential total number of novel Coronavirus cases in Wuhan City, China” (2020).
  3. Lu H., et al. “Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle”. Journal of Medical Virology 4 (2020): 401-402.
  4. Kim Y., et al. “Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor”. PLoS Pathogen3 (2016): e1005531.
  5. Channappanavar R., et al. “Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection”. Journal of Immunology 10 (2017): 4046-4053.
  6. Zumla A., et al. “Coronaviruses-drug discovery and therapeutic options”. Nature Reviews Drug Discovery 5 (2016): 327-347.
  7. National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3) (2020).
  8. Chu CM., et al. “Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax3 (2004): 252-256.
  9. Arabi YM., et al. “Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial”. Trials 1 (2018): 81.
  10. Wang Y., et al. “Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection”. Journal of Infectious Diseases10 (2019): 1688-1698.
  11. Sheahan TP., et al. “Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 1 (2020): 222.
  12. Agostini ML., et al. “Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease”. mBio2 (2018): e00221-18.
  13. Chow EJ., et al. “Influenza virus-related critical illness: prevention, diagnosis, treatment”. Critical Care 1 (2019): 214.
  14. Bleibtreu A., et al. “Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016”. BMC Infectious Diseases 18 (2018): 331.
  15. Xia S., et al. “A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike”. Science Advances 4 (2019): eaav4580.
  16. Coleman CM., et al. “Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion”. Journal of Virology 19 (2016): 8924-8933.
  17. Ji S., et al. “Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease”. Biomedicine and Pharmacotherapy 121 (2020): 109652.
  18. Ding Y., et al. “The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function”. BMC Complementary and Alternative Medicine 1 (2017): 130.


Citation: Nayab Mustansar and Rizwan Rafi. “Treatment Options for Novel Corona Virus-Current guidelines in Clinical Settings of Pakistan". Acta Scientific Pharmaceutical Sciences 4.6 (2020): 01-02.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US